425: Alumis to Acquire ACELYRIN in All-Stock Merger, Creating Late-Stage Biopharma with Extended Runway

Alumis Inc. and ACELYRIN, Inc. have announced a definitive agreement for an all-stock merger, aiming to create a well-capitalized, late-stage clinical biopharmaceutical company focused on immune-mediated diseases.

Summary

• Alumis Inc. and ACELYRIN, Inc. have entered into a merger agreement where Alumis will acquire ACELYRIN in an all-stock transaction.
• ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each ACELYRIN share they own.
• Post-merger, Alumis stockholders will own approximately 55% and ACELYRIN stockholders approximately 45% of the combined company.
• The combined company will have approximately $737 million in pro forma cash as of December 31, 2024, extending the cash runway into 2027.
• The merged entity will operate under the Alumis name and be led by the current Alumis executive team.
• The Alumis Board will expand to nine directors, including two additional directors from ACELYRIN's Board.
• The transaction is expected to close in the second quarter of 2025, pending stockholder approvals and customary closing conditions.
• The combined company will focus on developing and commercializing transformative therapies for immune-mediated diseases, with a differentiated pipeline and multiple upcoming milestones.
• Key pipeline assets include ESK-001 (TYK2 inhibitor) with Phase 3 topline data expected in 1Q 2026 for moderate-to-severe plaque psoriasis and Phase 2b topline data in 2026 for systemic lupus erythematosus, and A-005 (TYK2 inhibitor) with Phase 2 clinical trial initiation planned for MS in 2025.
• The merger also includes lonigutamab, a subcutaneously delivered anti-IGF-1R for thyroid eye disease (TED), with committed capital for clinical development.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting the potential for value creation and the strength of the combined pipeline. The extended cash runway and upcoming milestones contribute to a favorable sentiment.

Positives

• The merger creates a well-capitalized, late-stage biopharma company.
• The combined company has a strong cash position of approximately $737 million, extending the runway into 2027.
• The pipeline includes multiple near-term catalysts with upcoming clinical readouts.
• The addition of lonigutamab provides a potential best-in-class therapy for thyroid eye disease (TED).
• The combined company benefits from a world-class leadership team with a proven track record.
• The merger leverages extensive genetic insights to inform TYK2 indications, increasing the probability of technical success.
• ESK-001 has shown promising clinical responses in psoriasis trials, with potential for high efficacy and long-term safety.
• A-005 is a potentially first-in-class, fully CNS-penetrant TYK2 inhibitor with broad opportunities in neuroinflammatory diseases.

Negatives

• The merger is subject to stockholder approvals and customary closing conditions, which could delay or prevent the transaction.
• The integration of ACELYRIN's operations and personnel may present challenges.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• Clinical development timelines are subject to inherent risks and uncertainties, including potential delays in initiating, enrolling, or completing trials.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals of the proposed transaction, including stockholder approvals, may not be received.
• The announcement, pendency, or completion of the proposed transaction may negatively impact Alumis' or ACELYRIN's ability to attract and retain key personnel.
• The proposed transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the proposed transaction could arise.
• Economic, business, and/or competitive factors may adversely affect Alumis or ACELYRIN.
• Restrictions during the pendency of the proposed transaction may impact Alumis' or ACELYRIN's ability to pursue certain business opportunities.
• The anticipated benefits and synergies of the proposed transaction may not be fully realized or may take longer to realize than expected.
• Legislative, regulatory, economic, competitive, and technological changes could impact the combined company.
• The value of Alumis securities to be issued in the proposed transaction is subject to market fluctuations.
• Integration of the proposed transaction post-closing may not occur as anticipated.
• The combined company may not be able to achieve the growth prospects expected from the transaction.
• The market price of the common stock of each of Alumis and ACELYRIN may be affected by the announcement, pendency, or completion of the proposed transaction.
• Challenges are inherent in developing, commercializing, manufacturing, launching, marketing, and selling potential existing and new products and product candidates.
• The scope, progress, results, and costs of developing Alumis' and ACELYRIN's product candidates are subject to uncertainties.
• The timing and costs involved in obtaining and maintaining regulatory approval for Alumis' and ACELYRIN's current or future product candidates are uncertain.
• The market for, adoption, pricing, and reimbursement of Alumis' and ACELYRIN's product candidates, if approved, are subject to uncertainties.
• Uncertainties exist in contractual relationships, including collaborations, partnerships, licensing, or other arrangements.
• The ability of each of Alumis and ACELYRIN to establish and maintain intellectual property protection for products or avoid or defend claims of infringement is uncertain.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials could occur.

Future Outlook

The combined company expects to operate with a cash runway into 2027, driven by the pro forma cash position. They plan to advance multiple clinical programs, including ESK-001, A-005, and lonigutamab, with key data readouts expected in the near term.

Industry Context

This merger reflects a trend in the biopharmaceutical industry to consolidate assets and pipelines to create more robust and diversified companies. The focus on immune-mediated diseases aligns with the growing market for targeted therapies in this area. The combination of Alumis' and ACELYRIN's assets aims to create a stronger competitor in the space.

Comparison to Industry Standards

• The document mentions SOTYKTU, TREMFYA, HUMIRA, and SKYRIZI as existing treatments for psoriasis, indicating the competitive landscape.
• The document references the TYK2 P1104A loss-of-function variant, which is a key genetic insight used to inform the development of TYK2 inhibitors, similar to how other companies leverage genetic data to develop targeted therapies.
• The document mentions the LUMUS trial design incorporates learnings from past SLE trials, addressing challenges such as high placebo response rates, which is a common issue in SLE clinical development.
• The document compares ESK-001 PASI 75 OLE response rates to date in high biologics range, suggesting a competitive efficacy profile.

Management Changes

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the merger, with Alumis shareholders owning approximately 55% and ACELYRIN shareholders owning approximately 45% of the combined company.
• Employees of both companies may experience changes as a result of the integration of operations.
• Patients may benefit from the development of new therapies for immune-mediated diseases.
• The combined company's suppliers and partners may see changes in their relationships as a result of the merger.

Next Steps

• Obtain approval from Alumis and ACELYRIN stockholders.
• Satisfy other customary closing conditions.
• Finalize the clinical development plan for lonigutamab.
• Initiate Phase 2 study in MS patients with A-005 in 2H25.
• Advance ESK-001 through Phase 3 trials and prepare for potential regulatory submissions.

Key Dates